Chemotherapy-Free Strategy Based on Complete Pathologic Response With Subcutaneous Trastuzumab-Pertuzumab and T-DM1 in Early-Stage HER2-Positive Breast Cancer (PHERGAIN-2)
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: MEDICA SCIENTIA INNOVATION RESEARCH, SL
- Phase: II
- Execution start: 03/09/2021
- End of execution: 30/12/2022
- IP: ISABEL BLANCAS LOPEZ-BARAJAS
